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The molecular mechanism of Kaposi's sarcoma-associated herpesvirus (KSHV, human herpesvirus 8) entry is poorly understood. We tested a
broad variety of cell types of diverse species and tissue origin for their ability to function as targets in a quantitative reporter gene assay for KSHV-
glycoprotein-mediated cell fusion. Several human, non-human primate, and rabbit cell lines were efficient targets, whereas rodent and all human
lymphoblastoid cell lines were weak targets. Parallel findings were obtained with a virion entry assay using a recombinant KSHV encoding a
reporter gene. No correlation was observed between target cell activity and surface expression of α3β1 integrin, a proposed KSHV receptor. We
hypothesize that target cell permissiveness in both the cell fusion and virion entry assays reflects the presence of a putative KSHV fusion–entry
receptor.
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Kaposi's sarcoma-associated herpesvirus (KSHV, a gamma-
herpesvirus formally designated human herpesvirus 8) is
etiologically linked to the pathogenesis of Kaposi's sarcoma,
peripheral effusion lymphoma, and multicentric Castleman's
disease (Bubman and Cesarman, 2003). These pathologies
occur more frequently in people with acquired immunodefi-
ciency syndrome (AIDS) and in other settings of severe
immunodeficiency. Whereas the clinical burden of KSHV is
underscored by the plethora of virus-associated syndromes,
little is known about how the virus enters cells. Entry
mechanisms of enveloped viruses invariably involve fusion
between viral and cellular membranes, mediated by specific
virus-encoded glycoproteins (Earp et al., 2004). For herpes-
viruses, initiation of infection generally involves virion
attachment to the target cell surface followed by specific
interactions between viral envelope glycoproteins and one or⁎ Corresponding author. Fax: +1 301 480 1147.
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doi:10.1016/j.virol.2006.06.009more cellular entry receptors (Spear and Longnecker, 2003). In
most cases, these glycoprotein–receptor interactions lead to
direct fusion between the virion and plasma membranes;
alternatively, in some instances, they may induce virion
internalization into endosomes where the mildly acidic pH
triggers viral glycoprotein-induced fusion with the endosomal
membrane. By either route, the viral nucleocapsid is introduced
into the cytotosol, thereby setting the stage for the subsequent
steps of the virus life cycle.
KSHV infection in culture has been studied using both cell-
free virus and cell–cell transmission systems (Bubman and
Cesarman, 2003). Analyses of KSHV entry have yielded
evidence for both direct fusion and endocytic mechanisms
(Akula et al., 2003; Dezube et al., 2002; Inoue et al., 2003;
Pertel, 2002). In the present report, we employed two distinct
reporter gene assay systems to analyze the activity and
selectivity of the processes involved in the first step in the
infection cycle: a cell fusion assay to quantify KSHV
glycoprotein function and a virion entry assay to measure the
entry-dependent delivery of a constitutively activatable reporter
gene. Both systems revealed that cells from diverse species and
Fig. 1. Surface expression and functional activity of KSHV glycoproteins on
TPA-activated BCBL-1 cells. (A) Surface expression analyzed by flow
cytometry. BCBL-1 cells were cultured in the absence (blue) or presence of
TPA (5 ng/ml) for 24 h (green), or 48 h (red), then stained with rabbit peptide
antisera (gBN3, gH2, gL2, K8.1N3), followed by FITC-conjugated goat anti-
rabbit IgG. As background controls, cells were stained with the corresponding
pre-immune sera (black). (B) Functional activity analyzed by cell fusion assay.
BCBL-1 effector cells (+BCBL-1) pretreated with TPA for the indicated times
were mixed with HeLa target cells; as a background control, the BCBL-1 cells
were omitted (−BCBL-1). Cell fusion was assayed by measuring β-gal by both
in situ staining (photomicrographs) and calorimetric assay of NP-40 lysates of
parallel co-cultures (values below, duplicate samples±SD).
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support for a putative KSHV fusion–entry receptor(s), distinct
from the cellular molecules previously implicated in KSHV
attachment and entry.
Results
Cell fusion mediated by effector cells expressing KSHV
glycoproteins
To directly study the functional activity of KSHV glycopro-
teins, a vaccinia-based cell fusion assay system was devised in
which fusion of “effector cells” expressing the required KSHV
glycoproteins with “target cells” presumably expressing the
appropriate receptor(s) activated the LacZ reporter gene. Cell
fusion assays require only the minimal molecular components
of both virus and cell involved in the fusion mechanism,
independent of downstream post-entry events in the virus
replication cycle. Such analyses have proven particularly
valuable for studying viruses that enter by direct fusion with
the plasma membrane, the major entry mechanism for members
of the Herpesviridae family (Spear and Longnecker, 2003).
Indeed, cell fusion assays, in several cases using the minimal
number of essential recombinant viral glycoproteins, have been
developed for all three herpesvirus subfamilies: alpha (Klupp et
al., 2000; Maresova et al., 2001; Muggeridge, 2000; Pertel et al.,
2001; Tiwari et al., 2004; Turner et al., 1998), beta (Kinzler and
Compton, 2005; Santoro et al., 1999), and gamma (Haan et al.,
2001; Pertel, 2002; Wu et al., 2005).
Two types of effector cells were employed in the present
studies: BCBL-1 cells chronically infected with KSHVand cells
expressing recombinant KSHV glycoproteins. BCBL-1 cells
harbor the KSHV genome in a latent state; treatment with
phorbol esters induces expression of lytic phase genes,
including those encoding the glycoproteins of the viral
envelope. The expression patterns of gB, gH, gL, and K8.1A
on the surface of BCBL-1 cells were analyzed by flow
cytometry, using polyclonal antisera against peptides represen-
ting sequences from each glycoprotein. These glycoproteins
were chosen because they are detected in purified KSHV virion
preparations (Bechtel et al., 2005; Naranatt et al., 2002; Zhu et
al., 2005) and have been directly implicated in virus attachment
and/or entry (Akula et al., 2001a; Birkmann et al., 2001;
Naranatt et al., 2002; Wang et al., 2001, 2003) as well as
membrane fusion (Pertel, 2002). As shown in Fig. 1A, surface
expression of the four glycoproteins was low but detectable in
untreated BCBL-1 cells; the levels were greatly enhanced by
12-O-tetradecanoyl-phorbol-13-acetate (TPA) treatment in a
time-dependent fashion over 24–48 h, as assessed by both
fluorescence intensity and the percentage of positive cells
(approaching 100% for all). Immunoblot analyses of cell lysates
confirmed low-level expression of all four glycoproteins in
untreated cells and progressive increases over the 24–48 h
period of TPA treatment (not shown). The ability of BCBL-1
cells to function as effectors in the cell fusion assay was
demonstrated by measuring β-galactosidase (β-gal) activity
both by in situ staining of fixed cells and by spectrophotometricassay of nonionic detergent cell lysates (Fig. 1B). Low-level
fusion was observed with uninduced BCBL-1 effectors, and the
signal was greatly increased with BCBL-1 effectors that had
been pre-activated with TPA for 24–48 h; no β-gal was detected
in the absence of BCBL-1 effectors. This fusion pattern is
consistent with the KSHV surface glycoprotein expression data
described above.
Several criteria were employed to verify that the fusion
observed with BCBL-1 effector cells reflected the activity of the
surface KSHV glycoproteins. The cell fusion effector activities
were compared for KSHV-positive (chronically infected
lymphoma-derived BC-3, BC-1, and BCBL-1) versus KSHV-
negative (Burkitt's lymphoma-derived CA-46 and Ramos RA-1,
and NIH-3T3 murine fibroblast) cell lines. These effector cells
were either untreated, pretreated with TPA for 24 h, or untreated
and transfected with plasmids encoding the KSHV glycopro-
teins gB, gH, gL, and K8.1A. Flow cytometry analyses (not
shown) confirmed low surface expression of gB, gH, gL, and
K8.1A on untreated KSHV-positive cell lines and increased
expression upon TPA treatment or plasmid transfection; by
contrast, the viral glycoproteins were undetectable on the
Fig. 3. Specificity of cell fusion mediated by BCBL-1 effectors. (A) Specific
inhibition of fusion by antibodies to KSHV glycoproteins. Effectors (TPA-
treated BCBL-1 cells) were pre-incubated with the indicated concentrations of
purified IgG from rabbit antisera against the gB N-terminus (gBN1,○), gH (gH2,
⋄), K8.1A (K8.1N3, □), gL (gL2, ▵), and gB C-terminus (gBC, X). After
washing, the effectors were assayed for cell fusion with PCI-13 targets. (B)
Specificity of fusion mediated by KSHV-glycoprotein-transfected effectors
versus TPA-activated BCBL-1 effectors. Murine F-515 cells transfected with
control vector (open bars) or a combination of plasmids encoding gBΔ, gH, gL,
and K8.1A (hatched bars), or BCBL-1 cells treated with TPA for 24 h (black
bars) were used as effectors; fusion assays were performed with the indicated
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efficiently expressed upon plasmid transfection. For each of the
KSHV-positive effectors (Fig. 2A), significant fusion was
observed with untreated cells and was enhanced several fold by
either TPA pretreatment or KSHV glycoprotein transfection. By
contrast, the KSHV-negative effectors (Fig. 2B) failed to fuse,
without or with TPA pretreatment, but were rendered highly
fusogenic by KSHV glycoprotein transfection. Thus, the non-
fusogenic phenotypes of the KSHV-negative effectors were due
not simply to their inherent inability to undergo membrane
fusion or to support the reporter gene readout, but instead to
their lack of surface molecular components capable of inducing
cell fusion.
As a direct test of whether fusion mediated by TPA-activated
BCBL-1 effectors reflected KSHV glycoprotein function, anti-
peptide antibodies (IgG fractions from rabbit antisera) against
the glycoproteins of interest were analyzed for their effects on
fusion (Fig. 3A). Anti-gBN1 against a peptide based on the
N-terminal extracellular segment of gB strongly inhibited
KSHV fusion in a dose-dependent manner, as did anti-gH2
against a peptide derived from gH. Dose-dependent inhibition
was also observed with antibodies against peptides derived from
gL and K8.1A, although the effects were less pronounced. As
expected, no fusion inhibition was observed with anti-gBC
against a peptide based on the cytoplasmic C-terminal segment
of gB. The corresponding pre-immune IgG fractions had no
effect (not shown). As specificity controls (not shown), the
same antibodies had no effect on HIV-1 fusion, i.e. between
effectors expressing vaccinia-encoded HIV-1 Env glycoprotein
and targets expressing vaccinia-encoded CD4 and coreceptor;Fig. 2. Comparison of cell fusion effector activities of KSHV-positive (A) or
KSHV-negative (B) cell lines. Effectors were prepared from the indicated cell
lines that were untreated (open bars), TPA-treated for 24 h (black bars), or
untreated and transfected with a combination of plasmids encoding gBΔ, gH, gL,
and K8.1A (hatched bars). Effector cells were mixed with human PCI-13 targets,
and cell fusion was assessed by measuring β-gal in NP-40 lysates (duplicate
samples±SD).
target cells. In both panels, β-gal activity in NP-40 cell lysates was measured
(duplicate samples±SD).conversely, an anti-Env MAb potently inhibited HIV-1 fusion
but had no effect on KSHV fusion.
As a final validation for using TPA-activated BCBL-1 cells
as effectors in cell fusion assays, their ability to fuse with
different target cells was compared to that of effectors
expressing recombinant KSHV glycoproteins (Fig. 3B). With
both types of effector cells, minimal fusion occurred with NIH-
3T3 (murine) targets, whereas potent fusion was obtained with
BSC-1 (African green monkey, AGM) as well as HeLa (human)
and PCI-13 (human) targets. Taken together, these results
validate the use of either TPA-activated BCBL-1 cells or
recombinant glycoprotein-expressing cells as effectors in
KSHV cell fusion assays. The former were chosen for the
studies described below because they consistently expressed the
required glycoproteins without the potential variability asso-
ciated with cotransfection of multiple plasmids.
Broad target cell selectivity of KSHV-glycoprotein-mediated
fusion
An extensive panel of primary cells and established cell lines
of different tissue and species origin were tested for their ability
to serve as cell fusion targets with TPA-treated BCBL-1
effectors (Table 1). Based on the β-gal activities, a fusion index
Table 1
Fusion permissiveness of various target cell lines with TPA-activated BCBL-1
effectors
Species
type
Target cell lines β-gal
(OD/
min×103)
Fusion
index a
Derivative tissue Name
Rodent Mouse embryo fibroblast NIH-3T3 4 Weak
Mouse skin tumor F-515 6
Syrian baby hamster kidney
fibroblast
BHK-21 9
Rabbit Kidney epithelium RK-13 576 Strong
Monkey Kidney fibroblast CV-1 158 Strong
Kidney epithelium BSC-1 302
Kidney epithelium Vero 1241
Human Acute monocytic leukemia THP-1 1 Weak
Chronic myelogenous leukemia K-562 7
Acute lymphoblastic leukemia HSB-2 6
Acute lymphoblastic leukemia KG-1 2
Lymphoblastic Burkitt's
lymphoma
Ramos-
RA 1
3
Lymphoblastic Burkitt's
lymphoma
CA46 6
Colon carcinoma CoLau-467 4
Hepatocellular carcinoma Hu-H7 4
Umbilical vein endothelium HUVEC 81 Moderate
Dermal microvascular
endothelium
HMVEC-d 57
Muscle spindle
rhabdomyosarcoma
RD 136
Renal epithelium (Ad-E1A,
SV40T)
293T 71
Foreskin fibroblast HFF 43
Epithelial cervical
adenocarcinoma
HeLa 92
Ovarian adenocarcinoma SK-OV-3 158 Strong
Head/Neck squamous cell
carcinoma
PCI-13 988
Epithelial astrocytic
glioblastoma
U-87 MG 759
Oligodendroglioma MO3.13 458
Melanoma Mel-1700 408
a Arbitrary cut-offs (β-gal, OD/min×103) forWeak: 0–10;Moderate: 11–150;
and Strong: >150.
Fig. 4. Specificity of target cell non-permissiveness for KSHV fusion. (Left
panel) NIH-3T3 and F-515 cells (both weakly permissive for KSHV fusion)
were infected with recombinant vaccinia viruses encoding CD4 and CXCR4 and
tested for their ability to function as targets for HIV-1 fusion with TPA-treated
BCBL-1 effector cells expressing vaccinia-encoded HIV-1 Env, IIIB isolate (+).
(Right panel) CA46 and PCI-13 cells (Weak and Strong targets for KSHV
fusion, respectively) were infected with recombinant vaccinia viruses encoding
CD4 and CCR5 and tested for their ability to function as targets for HIV-1 fusion
with TPA-treated BCBL-1 effector cells expressing vaccinia-encoded HIV-1
Env, Ba-L isolate (+). In both panels, controls were performed with TPA-treated
BCBL-1 effectors not expressing HIV-1 Env (−). β-gal was measured in NP-40
cell lysates (duplicate samples±SD).
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All three rodent cell lines tested (hamster, mouse) scored Weak,
whereas the single rabbit and three AGM cell lines scored
Strong or Moderate. Among the panel of human cell types
tested, the fusion index ranged fromWeak to Strong, with all the
lymphoblastoid cell lines falling in the Weak category.
It was important to test whether the Weak target cell per-
missiveness of certain cell types was selective for KSHV-
glycoprotein-mediated cell fusion and did not simply reflect
artifactual aspects of the cell fusion assay. To this end, we
examined the ability of several Weak KSHV fusion targets to
function in an independent cell fusion system, i.e. as targets for
fusion mediated by HIV-1 Env glycoprotein when expressing
the corresponding recombinant receptors (CD4 and coreceptor
CXCR4 or CCR5). Fig. 4 (left panel) shows that murine NIH-
3T3 and F515 cells expressing recombinant CD4 and coreceptorwere highly permissive fusion targets for BCBL-1 effectors
expressing recombinant HIV-1 Env glycoprotein, but remained
weak KSHV fusion targets (i.e. BCBL-1 effectors lacking HIV-1
Env). We also tested lymphoblastoid cells that showed Weak
KSHV fusion target activity. Fig. 4 (right panel) shows that
expression of recombinant CD4 and coreceptor on CA46
Burkitt's lymphoma cells rendered them highly permissive for
HIV-1 fusion, although they remained Weak targets for KSHV
fusion. As expected, PCI-13 cells expressing recombinant CD4
and coreceptor were highly permissive with BCBL-1 effectors
lacking (i.e. KSHV fusion) or expressing HIV-1 Env. Additional
experiments (not shown) demonstrated similar phenomena with
K-562 leukemia cells and BJAB B cell lymphoma cells, which
were rendered highly permissive as HIV-1 fusion targets upon
expression of recombinant CD4 and coreceptor. Thus, the Weak
target cell phenotype of these cells was specific for KSHV fusion
and did not simply reflect their general refractoriness to
membrane fusion or their inability to support the vaccinia-
based reporter gene readout of this assay system.
Target cell selectivity of KSHV virion entry parallels KSHV cell
fusion
As a complementary method to assess the target cell
selectivity of KSHV glycoprotein activity, a virus entry assay
was employed, using a recombinant KSHV containing the
enhanced green fluorescent protein (EGFP) gene linked to a
constitutive cellular promoter (Vieira and O'Hearn, 2004).
Since EGFP expression was strictly dependent on virion entry
but did not require expression of any KSHV genes, this assay
accurately reflected the target cell selectivity of virus entry as
long as the cells examined were permissive for the post-entry
steps essential for the reporter gene readout. Fig. 5 shows
representative KSHV virion entry data for several target cell
Fig. 5. Susceptibility to KSHV entry of various target cells. The indicated target cells were pre-incubated with a 1:4 dilution of concentrated supernatant containing
recombinant rKSHV.219 virions then washed and cultured. Virus entry was monitored between 2 and 5 days by flow cytometry to detect EGFP-positive cells (open
histograms). Uninfected cells cultured for comparable times served as negative controls (filled histograms). Fusion index is based on the assignments in Table 1.
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following exposure to KSHV virions. A consistent correlation
was observed between target cell susceptibility in the KSHV
virion entry assay and permissiveness for KSHV fusion. Thus,
of the nine cell lines examined, six supported KSHV entry as
illustrated by the prominent peaks of EGFP-positive cells (Mel-
1700, Vero, BSC-1, HeLa, RD, HFF); these findings parallel the
Strong or Moderate activities of these cell lines as KSHV fusion
targets (Table 1). By contrast, three cell lines (BHK-21, K-562,
THP-1) did not support KSHVentry, consistent with their Weak
target activities for KSHV cell fusion (Table 1).
Lack of correlation between KSHV target cell permissiveness
and α3β1 integrin expression
The α3β1 integrin has been implicated as a receptor for
KSHVentry (Akula et al., 2002). Therefore, it was important to
compare surface expression of this integrin complex on human
target cell types with varying permissiveness as KSHV targets.
The data in Fig. 6 do not indicate a correlation between these
parameters. Thus, RD cells, which were Moderate targets for
KSHV fusion (Table 1, Fig. 6) and virion entry (Fig. 5),
displayed negligible α3β1 integrin surface expression (Fig. 6);
by contrast, the Weak fusion targets HSB-2 and CoLau-467
(Table 1, Fig. 6) expressed very high surface levels of α3β1
integrin (Fig. 6).
Discussion
In the present study, we demonstrate that a broad range of
cell types from different tissues and species are permissive forboth KSHV-glycoprotein-mediated cell fusion and KSHV
virion entry, consistent with the interpretation that both
processes reflect the same underlying mechanism of KSHV
glycoprotein function. Our findings are in close agreement
with a recent analysis of the host range for KSHV virion
infectivity in vitro, which measured expression of the viral
ORF73 gene as a marker of entry and latent phase gene
expression (Bechtel et al., 2003). In that study, all adherent
cell lines tested were shown to be susceptible to infection
(including human HeLa and 293 cells as well as monkey CV-1
cells, all of which scored Moderate or Strong in our fusion
assay); by contrast, the murine and hamster cell lines
examined (including NIH-3T3 cells studied herein) were
considerably less susceptible, consistent with our observation
of Weak fusion activities of rodent target cells. Interestingly,
all the human lymphoblastoid cells tested (including B-cell
lymphomas such as RAMOS cells analyzed in this report)
were reportedly resistant to infection, in agreement with our
demonstration of Weak target cell activities of such cell types
in both the cell fusion and entry assays. These latter results
remain puzzling since B cells are believed to be major sites for
KSHV infection in infected people (Bubman and Cesarman,
2003). Additional experiments are required to identify the
various factors contributing to differences between in vitro and
in vivo findings, e.g. altered characteristics of transformed cell
lines, possible influences of cell activation and changes
associated with adaptation to cell culture.
We favor the hypothesis that a major route for KSHV entry
involves a sequence of distinct molecular events that culminate
in direct fusion of the virion envelope with the target cell plasma
membrane. In this model, the mechanistic cascade is initiated
Fig. 6. Surface expression of α3β1 integrin on various human cells lines. The
indicated cells were analyzed by flow cytometry using murine MAb P1B5
against human α3β1 integrin (open histograms). Mouse IgG1 was used as an
isotype control (black histograms). Cell fusion activities (β-gal in NP-40 cell
lysates, mean of duplicate samples) were obtained with the same target cell
preparations and are consistent with the fusion index as assigned in Table 1.
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surface “fusion–entry” receptor(s). Indeed, for glycoproteins
from several herpesviruses, cell fusion assays have documented
the absolute requirement for such a receptor (Browne et al.,
2001; Pertel et al., 2001; Santoro et al., 1999; Terry-Allison et
al., 2001; Tiwari et al., 2004). The simplest interpretation of the
present results is that KSHV target cell permissiveness is
dependent on surface expression of a specific KSHV fusion–
entry receptor(s) and that the non-permissive targets display
insufficient levels of such a receptor. However, we cannot rule
out an alternative explanation that non-permissiveness results
from a dominant negative inhibitory factor(s) selective for
KSHV or that factors besides receptor expression contribute to
the differences in fusion and entry observed in our assay
systems. Our results also do not exclude the possibility that, in
some instances, e.g. with certain target cell types, KSHV might
initiate infection via the alternative entry route of endocytosisfollowed by low-pH activation of viral glycoprotein function
(Akula et al., 2002, 2003; Inoue et al., 2003; Wang et al., 2003).
Such a context-dependent mechanism, which has been demon-
strated for herpes simplex virus type I (Nicola et al., 2003),
would likely involve molecular events distinct from those
involved in the direct fusion pathway.
Several types of cell surface molecules have been proposed
to function as KSHV receptors, most notably α3β1 integrin in
human dermal microvascular endothelial cells and human
foreskin fibroblasts (Akula et al., 2002) and heparan sulfate
(Akula et al., 2001b; Birkmann et al., 2001). Each has been
shown to interact with specific KSHV glycoproteins, the
former with gB (Wang et al., 2003) and the latter with both gB
(Akula et al., 2001a) and K8.1A (Birkmann et al., 2001; Wang
et al., 2001). However, our results do not indicate a direct role
for α3β1 integrin in KSHV-glycoprotein-mediated cell fusion
or in KSHV virion entry, at least for the cell types examined in
this report. Nonetheless, the possible involvement of these
surface molecules can be considered in a broader context since
the internalization of enveloped viruses from many families
(including other herpesviruses) can be strongly influenced by
various integrins (Triantafilou et al., 2001) and by sulfated
proteoglycans (Liu and Thorp, 2002; Shukla and Spear, 2001).
The recent report that DC-SIGN facilities KSHV entry into
myeloid dendritic cells and macrophages (Rappocciolo et al.,
2006) is also noteworthy in view of emerging evidence
implacating C-type lectins in interactions of many viruses with
the cell surface of target cells (Altmeyer, 2004). These surface
entities play important roles in facilitating entry of many
viruses, in some cases by serving as attachment factors to
enhance virus adsorption to the cell; in addition, they may
participate in signaling pathways that influence infectivity in
ways that do not directly involve the specific entry mechan-
ism. These considerations highlight the difficulties in defining
the molecular elements that comprise the essential entry
machinery and in distinguishing them from factors that play
important accessory roles. We believe that the prevailing data
point to the existence of a specific receptor(s) underlying the
primary KSHV entry route that is distinct from the molecules
implicated thus far. Indeed, by exploiting the ability of the cell
fusion and virion entry assays to isolate the functional
activities of the participating viral glycoproteins, we have
recently identified a KSHV fusion–entry receptor, a protein
whose known properties suggest possible interactions with the
integrin system (Kaleeba and Berger, 2006).
Materials and methods
Cell culture
Mouse tumor F-515 and humanMel-1700, SK-OV-3, PCI-13,
CoLau-467, and THP-1 cells were provided by Maurice
Zauderer and Ernest Smith (Vaccinex, Inc., Rochester, NY).
Primary HMVEC-d and HUVEC cells were obtained from
Clonetics Inc. (Walkersville, MD). All other cell lines were
obtained from either the American Type Culture Collection
(Manassas, VA) or the AIDS Research and Reference Reagent
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mended by the suppliers. For TPA treatment, cells were
cultured in the presence of 5 ng/ml TPA, which for BCBL-1
cells was sufficient to induce surface expression of KSHV
glycoproteins but suboptimal for production of progeny KSHV
particles.
Antibodies against KSHV glycoproteins
Rabbit polyclonal antibodies to KSHV glycoproteins were
generated using synthetic peptides predicted to be both immuno-
genic and/or surface-exposed on the respective mature glycopro-
teins, according to weighted scores from hydrophilicity, surface
probability, and backbone flexibility algorithms integrated in the
MacVector 7.0 software (Oxford Molecular-Accelrys, Burling-
ton, MA). Each peptide was designed with an additional C-
terminal Cys residue for conjugation to keyhole limpet
hemocyanin. New Zealand White rabbits were immunized
with 0.5 mg of conjugated peptide (Covance BP, Inc., PA). IgG
was purified from antisera on protein-A Sepharose 4B columns
(Amersham-Pharmacia Biotech, Piscataway, NJ) according to
standard procedures. Designations and sequences of the pep-
tides were as follows: gBN1 (gB 282–298, SDRGTSPTPQN-
RIFVET), gBN3 (gB 22–41, GAAHSRGDTFQTSSSPTPPG),
and gBC (gB 797–812, LQQEERQKADDLKKST); gH2 (gH
229–247, LPSLKGHATYDELTFARNA); gL2 (gL 139–158,
AMNRTGSVSGSQTRAKSSSR); K8.1N3 (K8.1 44–59, GQ-
VYQDWLGRMNCSYE).
Recombinant protein expression
Vaccinia-virus-based technology was employed for recom-
binant protein expression (Moss et al., 1998) and for cell fusion
assays (Dey and Berger, 2003) (see those review articles for
original citations regarding details of specific recombinant
vaccinia viruses). Infections of the indicated cells were
performed at an MOI of 5 for each virus; the cells were
incubated overnight in suspension at 31 °C to allow protein
expression then washed for subsequent analyses. The following
vaccinia recombinants containing the indicated cDNA linked to
a vaccinia early/late promoter were employed: vTF7-3,
bacteriophage T7 RNA polymerase, vCB3 encoding human
CD4, vCBYF1-fusin and vHC-1 encoding HIV-1 coreceptors
(CXCR4 and CCR5, respectively), and vCB41 and vCB43
encoding HIV-1 Env (strain IIIB, CXCR4-restricted and strain
Ba-L, CCR5-restricted, respectively). For expression of KSHV
glycoproteins, the pVOTE 2.1 expression vector (Ward et al.,
1995) containing the T7 promoter and regulatory elements from
the E. coli Lac operon was used to generate the following
plasmids encoding cDNAs for KSHV gH (pJK2-gH), gL
(pJK3-gL), K8.1A (pJK4-K8.1A), and truncated gB lacking the
C-terminal 58 amino acids (Pertel et al., 2001) (pJK1-gBΔ).
Cell fusion assay
KSHV-glycoprotein-mediated cell fusion was measured
using a vaccinia-virus-based reporter gene activation assayoriginally developed to study HIV Env (Nussbaum et al.,
1994) and subsequently applied to glycoproteins from many
families of enveloped viruses (Dey and Berger, 2003). Briefly,
two populations of single cell suspensions were prepared:
“effector cells” expressing KSHV glycoproteins (endogenous
or transfected) and vaccinia-encoded T7 RNA polymerase, and
“target cells” containing the vaccinia-encoded E. coli LacZ
gene linked to the T7 promoter. Effector and target cells were
mixed (typically 1×105 each, in 96-well flat-bottom plates,
0.2 ml total volume per well) and incubated at 37 °C for 1.5–
4 h. β-gal activity was measured either by colorimetric assay
of enzyme activity in 0.5% nonidet P-40 (NP-40) cell lysates
using as substrate chlorophenol red-β-D-galactopyranoside or
by in situ staining with 4-chloro-3-indolyl-β-D-galactopyranoi-
side substrate. For antibody inhibition studies, effector cells
were pre-incubated with the indicated antibodies for 60 min at
4 °C prior to mixing with target cells. All β-gal values shown
for cell lysate assays represent the mean of duplicate assay
wells, ±SD.
KSHV virion entry assay
KSHV virion entry was measured with the recombinant
virus rKSHV.219 (provided by Jeffrey Vieira), which
contains the EGFP reporter gene under control of the
constitutive cellular promoter for human elongation factor 1-
alpha. Virion stocks were prepared by concentrating the
supernatants of infected Vero cells as previously described
(Vieira and O'Hearn, 2004). The indicated target cells were
pre-incubated with rKSHV.219 virions for 90 min at 37 °C
then washed and cultured in DMEM supplemented with
10% Fetal Bovine Serum. Virion entry was monitored at 2–
5 days by flow cytometry to detect EGFP-positive cells.
Each infection was performed in duplicate, with equivalent
results.
Analysis of surface KSHV glycoproteins and integrins
BCBL-1 cells were pre-blocked with rabbit IgG and anti-
human CD32 (Fcγ-RII) blocker (Stem cell Technologies, Inc.,
Vancouver, Canada) then stained with primary antibodies (1:50
dilution of rabbit anti-peptide antisera against the indicated
KSHV glycoprotein) followed by fluorescein-isothiocyanate-
conjugated anti-rabbit secondary antibody (Dako, Dakopatts,
High Wycombe, UK). Cells were washed, resuspended in
staining media supplemented with 2% paraformaldehyde, and
analyzed on a FACScan flow cytometer (Becton Dickinson,
San Jose, CA). Layout and statistical parameters were analyzed
by FlowJo v4.5.9 software (Tree Star, Ashland, OR). To
analyze surface expression of α3β1 integrin, cells were
harvested in non-enzymatic cell dissociation reagent (Sigma)
and stained with murine MAb P1B5 against human α3β1
integrin (IgG1, Chemicon International, Temecula, CA) at 4 °C
for 30 min; murine IgG1 was used as a control primary
antibody. After two washes, cells were incubated in a 1:100
dilution of FITC-conjugated anti-mouse IgG and analyzed by
flow cytometry.
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